ClinicalTrials.gg
TerminatedNCT02132598Updated Mar 10, 2021Results posted

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

A Phase 2 interventional study of cabozantinib in Non Small Cell Lung Cancer (NSCLC) and Metastases to the Brain, sponsored by Liza Villaruz, MD. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-10.

Sponsored by Liza Villaruz, MD · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Why this study was terminated
Trial stopped due to slow patient accrual.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung — 3 open to participants now, 6 under way, none of them phase 3. cabozantinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
15th of 16
5 · median 39
Started
2015
the only one that year
Phase 2
10 of 16
3 open now
Registered
6th of 16
by date
Lead sponsor
1 of 16
Liza Villaruz, MD

Among the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 10 in phase 2, and was the 6th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cabozantinib

cabozantinib: first FDA approval 2012 (COMETRIQ), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing cabozantinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is an open-label phase II clinical trial designed to allow a preliminary assessment of the efficacy and safety of cabozantinib in unselected Non-Small Cell Lung Cancer (NSCLC) patients with metastases to the brain and in the subset of patients with c-MET amplified Non-Small Cell Lung Cancer with metastases to the brain. Previously treated patients with non-squamous NSCLC who have had brain metastases at any point in their treatment history are eligible for enrollment on this clinical trial. Patients with clinically asymptomatic untreated brain metastases will be allowed on trial at the discretion of the treating investigator. Patients who have undergone treatment for their brain metastases with Whole-Brain Radiation Therapy (WBRT), stereotactic radiosurgery (SRS) or surgery must be clinically stable and recovered from all procedures at the time of study enrollment.

Read the detailed description

This is a Phase 2, single-arm, open-label study of cabozantinib in subjects with molecularly unselected Non-Small Cell Lung Cancer (NSCLC) with metastases to the brain and in patients with c-MET amplified Non-Small Cell Lung Cancer (NSCLC) with metastases to the brain.

Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events. Treatment cycles are 4 weeks in duration.

The primary endpoint is Overall Response Rate (ORR) in both the unselected NSCLC population and the molecularly selected patients on the basis of c-MET amplification.

03

Conditions studied

  • Non Small Cell Lung Cancer (NSCLC)
  • Metastases to the Brain

Keywords

  • Lung Cancer
  • Non Small Cell
  • Brain metastases
  • c-MET
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Previously treated patients with non-squamous NSCLC who have had at any point in their treatment history are eligible for enrollment on this clinical trial. (Patients must have received at least one regimen for systemic disease which may be cytotoxic or oral tyrosine kinase inhibitor therapy.)

    • Patients with clinically asymptomatic untreated brain metastases will be allowed on trial at the discretion of the treating physician
    • Patients who have undergone treatment for their brain metastases with whole brain radiotherapy, stereotactic radiosurgery, or surgical resection must be clinically stable and recovered from all procedures at the time of study enrollment.
  2. Patients must have tumor tissue available for submission that is sufficient to complete c-MET Fluorescence in Situ Hybridization (FISH) studies as well as routine molecular profiling at the UPMC. Patients must agree to submission of these specimens as defined in Section 9.

    • c-MET amplification will be determined by FISH ratio (c-MET/CEP7) > 2.0, based on testing of the primary tumor and/or site of disease
    • Patients' tumors must undergo testing for Epidermal Growth Factor Receptor (EGFR) exon 19 deletion, EGFR exon 21 L858R substitution, and anaplastic lymphoma kinase (ALK) rearrangements. If positive, patients must have been treated with an appropriate tyrosine kinase inhibitors (TKI) prior to enrolling to the study.
  3. The subject has had an assessment of all extracranial disease sites (e.g., by computerized tomography (CT) scan, positron emission tomography-CT, and bone scan as appropriate) within 28 days before the first dose of cabozantinib.
  4. The subject must have a baseline brain MRI scan or CT scan of the head (in patients unable to obtain an MRI) within 14 days prior to first dose of cabozantinib.

    • Patients receiving must be on a stable dose of glucocorticoids during the 5 days prior to the baseline brain imaging.
  5. Patients must have as defined by (RECIST) v1.1
  6. Subjects having undergone recent resection or of an intracranial tumor will be eligible as long as all of the following conditions apply:

    • First dose of cabozantinib occurs at least 28 days after surgery, and the subject has recovered from the effects of surgery
  7. Age ≥18 years
  8. (ECOG) performance status ≤2 ( ≥60%)
  9. Patients must have normal organ and marrow function as defined below: (within 4 days of beginning treatment unless noted otherwise)

    • ≥9 g/dL
    • (ANC) ≥1,500/mm3 (no CSF support)
    • ≥100,000/mm3
    • ≤ 1.5 x (ULN)
    • Bilirubin (Gilbert's Disease) \< 3.0 mg/dL
    • (AST) (SGOT) ≤3.0 × ULN
    • Alanine Aminotransferase (ALT) (SGPT) ≤3.0 × ULN
    • Serum creatinine ≤ 1.5 x ULN
    • (CrCl) ≥40 mL/min
    • For creatinine clearance estimation, the Cockcroft and Gault equation should be used:
    • Male: CrCl (mL/min) = (140 - age) × wt (kg) / (serum creatinine × 72)
    • Female: Multiply above result by 0.85 ≤ 1.5 x ULN
    • Lipase (no radiologic or clinical evidence of pancreatitis) \< 2.0 x ULN
    • Urine protein/creatinine ratio (UPCR) ≤1
    • Serum phosphorus, calcium, magnesium and potassium ≥ LLN
  10. The subject is capable of understanding and complying with the protocol requirements and has signed the document.
  11. Women of must have a negative serum pregnancy test at screening.
  12. The effects of cabozantinib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry and for 4 months after the last dose of study drug, even if oral contraceptives are used.

Exclusion criteria

Exclusion Criteria:

  1. The subject has received cytotoxic chemotherapy (including cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies; including investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatment.
  2. The subject has received prior treatment with a small molecule kinase inhibitor or a hormonal therapy (including investigational kinase inhibitors or hormones) within 14 days or five half-lives of the compound or active metabolites, whichever is longer, before the first dose of study treatment.
  3. Prior treatment with cabozantinib or other c-MET directed therapy.
  4. The subject has received radiation therapy as follows:

    • To the thoracic cavity, abdomen or pelvis within 3 months of the first dose of study treatment or has with ongoing complications or is without complete recovery and healing from prior radiation therapy
    • To bone or within 14 days of the first dose of study treatment
    • To any other site(s) within 28 days of the first dose of study treatment
  5. The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment.
  6. The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or computerized tomography (CT) scan. The subject has not recovered to baseline or ≤ Grade 1 from toxicity due to all prior therapies except alopecia and other non- AEs.
  7. The subject has (PT)/ International Normalized Ratio (INR) or partial thromboplastin time (PTT) test ≥ 1.3 x the laboratory within 7 days before the first dose of study treatment.
  8. The subject is receiving concomitant treatment with warfarin, warfarin-related agents, or low molecular weight heparin (LMWH) at the time of study entry at therapeutic doses. Low-dose warfarin (≤ 1 mg/day) or LMWH at prophylactic doses are permitted.
  9. The subject has received enzyme-inducing anti-epileptic agents within 2 weeks before the first dose of cabozantinib (e.g., carbamazepine, phenytoin, phenobarbital, primidone). Other enzyme inducing agents prohibited within 2 weeks before the first dose of cabozantinib include rifampin, rifabutin, rifapentin, and St. John's Wort.
  10. The subject has experienced any of the following:

    • Clinically-significant gastrointestinal bleeding within 6 months before the first dose of study treatment b.Hemoptysis of ≥ 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of study treatment
    • Any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment
  11. The subject has radiographic evidence of cavitating pulmonary lesion(s)
  12. The subject has tumor abutting, invading or encasing any major blood vessels.
  13. The subject has evidence of tumor invading the Gastro Intestinal (GI) tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib.
  14. The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:

    • Cardiovascular disorders including:

      • Congestive heart failure (CHF): (NYHA) Class III (moderate) or Class IV (severe) at the time of screening
      • Concurrent uncontrolled hypertension defined as sustained BP > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal antihypertensive treatment within 7 days of the first dose of study treatment
      • Any history of congenital long syndrome
      • Any of the following within 6 months before the first dose of study treatment:

1.unstable angina pectoris 2.clinically-significant cardiac arrhythmias 3.stroke (including (TIA), or other ischemic event) 4.myocardial infarction (MI) 5.thromboembolic event requiring therapeutic anticoagulation (Note: subjects with a venous filter (e.g. vena cava filter) are not eligible for this study)

  • Gastrointestinal disorders particularly those associated with a high risk of perforation or fistula formation including:
  • Any of the following within 28 days before the first dose of study treatment

    1. Intra-abdominal tumor/ invading GI mucosa
    2. Active peptic ulcer disease,
    3. Inflammatory bowel disease (including ulcerative colitis and Crohn's disease), diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis
    4. Malabsorption syndrome
  • Any of the following within 6 months before the first dose of study treatment:

    1. Abdominal fistula
    2. Gastrointestinal perforation
    3. Bowel obstruction or gastric outlet obstruction
    4. Intra-abdominal abscess. Note: Complete resolution of an intra-abdominal abscess must be confirmed prior to initiating treatment with cabozantinib even if the abscess occurred more than 6 months before the first dose of study treatment.
  • Other disorders associated with a high risk of fistula formation including Percutaneous Endoscopic Gastrostomy (PEG) tube placement within 3 months before the first dose of study therapy.
  • Other clinically significant disorders such as:

    • Serious active infection requiring systemic treatment within 28 days before the first dose of study treatment.
    • Serious non-healing wound/ulcer/bone fracture within 28 days before the first dose of study treatment.
    • History of organ transplant
    • Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days before the first dose of study treatment.
  • History of surgery as follows:

    1. Subjects having undergone recent resection or of an intracranial tumor will be eligible as long as all of the following conditions apply: First dose of cabozantinib occurs at least 28 days after surgery, and the subject has recovered from the effects of surgery.
    2. Other minor surgery within 28 days of the first dose of cabozantinib if there were no wound healing complications. If there is evidence of wound dehiscence, subjects will be eligible for trial after a minimum of 3 months after surgery to the first dose of cabozantinib, provided complete wound healing is confirmed at least 28 days before the first dose of cabozantinib.
    3. Other major surgery within 2 months of the first dose of cabozantinib if there were no wound healing complications. If there is evidence of wound dehiscence, subjects will be eligible for trial after a minimum of 6 months after surgery to the first dose of cabozantinib, provided complete wound healing in confirmed at least 28 days before the first dose of cabozantinib.
    4. The subject is unable to swallow tablets.
    5. The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) >500 ms within 28 days before randomization. Note: if initial QTcF is found to be > 500 ms, two additional EKGs separated by at least 3 minutes should be performed. If the average of these three consecutive results for QTcF is ≤ 500 ms, the subject meets eligibility in this regard.
    6. The subject is pregnant or breastfeeding.
    7. The subject has a previously identified allergy or to components of the study treatment formulation.
    8. The subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee.
    9. The subject has had evidence within 2 years of the start of study treatment of another which required systemic treatment. Note: Subjects with a history of early stage or locally advanced non-metastatic prostate cancer within 2 years of the start of study treatment may be included in the study.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Cabozantinib (XL184)

    Patients will receive cabozantinib at 60 mg orally once daily and continue on treatment until disease progression, death or unacceptable adverse events. Treatment cycles are 4 weeks in duration

    Drug: cabozantinib

Interventions

  • Also known as: Cometriq, EXEL-7184, EXEL-02977184, CAS Registry# 1140909-48-3

06

What researchers measure

Primary outcomes

  1. Overall Response

    The proportion of response-evaluable patients who achieve Complete Response (CR) or Partial Response (PR) as best response by RECIST v1.1 criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.

    Time frame: Up to 12 months

Secondary outcomes

  1. Disease Control Rate (DCR)

    Proportion of response-evaluable patients that experienced Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) as best response (RECIST v1.1 criteria) per the total study population criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Stable Disease (SD) is defined as, neither sufficient shrinkage (compared to baseline) to qualify for partial or complete response (CR or PR) nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD).

    Time frame: Up to 16 weeks

  2. Progression-free Survival (PFS)

    Progression-free survival is the time measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression), whichever occurs first, with progression defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Up to 12 months

  3. Overall Survival (OS)

    The length of time from the start of treatment that patients remain alive, until death from any cause.

    Time frame: Up to 24 months

  4. Time to Progression (TTP)

    Time from initiation of study treatment to disease progression per RECIST v1.1, excluding death from causes unrelated to the disease. As defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Until disease progression; Up to 2 years

  5. Worst Grade of Adverse Events Reported

    Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

    Time frame: From baseline up to 20 weeks

  6. Worst Grade of AE at Least Possibly Related to Treatment Reported

    Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

    Time frame: From baseline up to 20 weeks

  7. Worst Grade of AE at Least Probably Related to Treatment Reported

    Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

    Time frame: From baseline up to 20 weeks

  8. Worst Grade of AE Definitely Related to Treatment Reported:

    Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

    Time frame: From baseline up to 20 weeks

07

Results

Posted Sep 16, 2020

Participant flow

Participant flow — Overall Study
MilestoneCabozantinib (XL184)
Started5
Completed5
Not completed0

Outcome measures

PrimaryOverall Response

The proportion of response-evaluable patients who achieve Complete Response (CR) or Partial Response (PR) as best response by RECIST v1.1 criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.

Time frame:
Up to 12 months
Reported as:
Number · proportion of participants
Overall Response
proportion of participantsCabozantinib (XL184)
Overall Response0.25 (0.006 to .806)
SecondaryDisease Control Rate (DCR)

Proportion of response-evaluable patients that experienced Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) as best response (RECIST v1.1 criteria) per the total study population criteria. Per RECIST v1.1, Complete Response (CR) is defined as disappearance of all target lesions; disappearance of all non-target lesions and normalization of tumor marker level. Partial Response (PR) is defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Stable Disease (SD) is defined as, neither sufficient shrinkage (compared to baseline) to qualify for partial or complete response (CR or PR) nor sufficient increase (taking as reference the smallest sum of diameters at baseline or while on study, whichever is smallest) to qualify for progressive disease (PD).

Time frame:
Up to 16 weeks

No measurements were reported for this outcome.

SecondaryProgression-free Survival (PFS)

Progression-free survival is the time measured from the initial date of treatment to the date of documented progression, or the date of death (in the absence of progression), whichever occurs first, with progression defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Up to 12 months
Reported as:
Number · days
Progression-free Survival (PFS)
daysCabozantinib (XL184)
Progression-free Survival (PFS)45
SecondaryOverall Survival (OS)

The length of time from the start of treatment that patients remain alive, until death from any cause.

Time frame:
Up to 24 months
Reported as:
Median · months
Overall Survival (OS)
monthsCabozantinib (XL184)
All patients4.07 (3.09 to NA)
c-MET positive patients (only)2.25 (0.43 to NA)
SecondaryTime to Progression (TTP)

Time from initiation of study treatment to disease progression per RECIST v1.1, excluding death from causes unrelated to the disease. As defined by RECIST v 1.1. Progressive disease (PD) is defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Until disease progression; Up to 2 years
Reported as:
Number · days
Time to Progression (TTP)
daysCabozantinib (XL184)
Time to Progression (TTP)45
SecondaryWorst Grade of Adverse Events Reported

Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

Time frame:
From baseline up to 20 weeks
Reported as:
Count of participants · Participants
Worst Grade of Adverse Events Reported
ParticipantsCabozantinib (XL184)
Grade 10
Grade 20
Grade 34
Grade 40
Grade 51
SecondaryWorst Grade of AE at Least Possibly Related to Treatment Reported

Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

Time frame:
From baseline up to 20 weeks
Reported as:
Count of participants · Participants
Worst Grade of AE at Least Possibly Related to Treatment Reported
ParticipantsCabozantinib (XL184)
Grade 10
Grade 20
Grade 35
Grade 40
Grade 50
SecondaryWorst Grade of AE at Least Probably Related to Treatment Reported

Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

Time frame:
From baseline up to 20 weeks
Reported as:
Count of participants · Participants
Worst Grade of AE at Least Probably Related to Treatment Reported
ParticipantsCabozantinib (XL184)
Grade 10
Grade 20
Grade 34
Grade 40
Grade 50
SecondaryWorst Grade of AE Definitely Related to Treatment Reported:

Worst Grade of Adverse Events Reported as assessed by the investigator. Severity/grade defined by the Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Subjects monitored continuously for Adverse Events (AE's) throughout the study and for 30 days after the last dose of study treatment.

Time frame:
From baseline up to 20 weeks
Reported as:
Count of participants · Participants
Worst Grade of AE Definitely Related to Treatment Reported:
ParticipantsCabozantinib (XL184)
Grade 10
Grade 20
Grade 31
Grade 40
Grade 50

Adverse events

Collected over Up to 30 days after discontinuation of treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cabozantinib (XL184)4/5 (80%)5/5 (100%)5/5 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventCabozantinib (XL184)
FatigueGeneral disorders2/5
Blood bilirubin increasedInvestigations2/5
HypertensionVascular disorders2/5
Infections and infestations - Other, specifyInfections and infestations1/5
Urinary tract infectionInfections and infestations1/5
Alkaline phosphatase increasedInvestigations1/5
GGT increasedInvestigations1/5
Lymphocyte count decreasedInvestigations1/5
Platelet count decreasedInvestigations1/5
AnorexiaMetabolism and nutrition disorders1/5
Most frequent other events
Showing 10 of 63
Most frequent other events
EventCabozantinib (XL184)
FatigueGeneral disorders5/5
HypomagnesemiaMetabolism and nutrition disorders4/5
DiarrheaGastrointestinal disorders3/5
Aspartate aminotransferase increasedInvestigations3/5
Blood bilirubin increasedInvestigations3/5
HypoalbuminemiaMetabolism and nutrition disorders3/5
HyponatremiaMetabolism and nutrition disorders3/5
Metabolism and nutrition disorders - Other, specifyMetabolism and nutrition disorders3/5
Sinus tachycardiaCardiac disorders2/5
ConstipationGastrointestinal disorders2/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cabozantinib (XL184)
Mean62.6 (51.0 to 76.8)
Sex: Female, Male
Sex: Female, Male(Participants)Cabozantinib (XL184)
Female5
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cabozantinib (XL184)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White5
More than one race0
Unknown or Not Reported0
c-MET amplification
c-MET amplification(Participants)Cabozantinib (XL184)
Negative3
Positive2
Histology
Histology(Participants)Cabozantinib (XL184)
ADENOCARCINOMA IN SITU, NOS1
ADENOCARCINOMA, NOS2
NON-SMALL CELL CA2
Stage of Disease
Stage of Disease(Participants)Cabozantinib (XL184)
Stage IV5
Stage l-III0
08

Study locations

1 site
  • University of Pittsburgh Cancer Institute- Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2015, a primary completion of Aug 2019 and a completion of Aug 2019. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2014
First posted
May 7, 2014
Start
Dec 2015
Primary completionActual
Aug 9, 2019
CompletionActual
Aug 9, 2019
Results first posted
Sep 16, 2020
Last update
Mar 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02132598
Lead sponsor
Liza Villaruz, MD
Collaborators
Exelixis
Responsible party
Liza Villaruz, MD (Assistant Professor of Medicine, University of Pittsburgh) — Sponsor-investigator
First posted
May 7, 2014
Start date
Dec 2015
Primary completion
Aug 9, 2019
Completion
Aug 9, 2019
Results posted
Sep 16, 2020
Last update
Mar 10, 2021

Study contacts

Liza Villaruz, MD
principal investigator · UPCI Department Hematology-Oncology

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabozantinib

Start the discussion